Jerome R Hoffman, MA, MD, Professor Emeritus of Medicine/Emergency Medicine; Richelle J Cooper, MD, MSHS, Associate Professor of Medicine/Emergency Medicine.
How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST-3)
Version of Record online: 8 OCT 2012
© 2012 The Authors. EMA © 2012 Australasian College for Emergency Medicine and Australasian Society for Emergency Medicine
Emergency Medicine Australasia
Volume 24, Issue 5, pages 473–476, October 2012
How to Cite
Hoffman, J. R. and Cooper, R. J. (2012), How is more negative evidence being used to support claims of benefit: The curious case of the third international stroke trial (IST-3). Emergency Medicine Australasia, 24: 473–476. doi: 10.1111/j.1742-6723.2012.01604.x
- Issue online: 8 OCT 2012
- Version of Record online: 8 OCT 2012
- 1IST-3 Collaborative Group, , , et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379 (9834): 2352–2363.
- 7Thrombolytics for acute ischemic stroke. The NNT: The NNT Group, 2010. Available from URL: http://www.thennt.com/thrombolytics-for-stroke [Accessed July 2012]..
- 19Rethinking Aging: Growing Old and Living Well in an Overtreated Society. Chapel Hill, NC: The University of North Carolina Press, 2011..